• Drug: Vosevi (sofosbuvir/velpatasvir/voxilaprevir)

  • Manufacturer: Gilead

  • Route of Administration: Oral

  • Site of Care: Outpatient

  • Approved Indication: treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis who have

    • genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor
    • genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor

  • Disease: chronic viral hepatitis C

  • Therapeutic Area: Infectious disease, Gastroenterology, Hepatology

  • Enrollment Form Link: MySupportPath

  • Phone Number: N/A

  • Fax Number: 1-855-298-8700
  • Product Website: N/A